title: Comparison of the Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema in Vitrectomized and Nonvitrectomized Eyes.
abstract: OBJECTIVE
  To compare the effectiveness of intravitreal ranibizumab (IVR) for diabetic macular edema (DME) between eyes with and without previous vitrectomy.
  
  
  METHODS
  We prospectively assessed the best-corrected visual acuity (BCVA) and central macular thickness (CMT) after IVR for 6 months.
  
  
  RESULTS
  There were no significant differences in the baseline BCVA and CMT between both groups. In the nonvitrectomized group (n = 15), the mean changes of BCVA and CMT from baseline to month 6 were significant (p < 0.01). In the vitrectomized group (n = 10), the improvement appeared to be slower, and the mean BCVA improvement was not significant (p = 0.5), although the mean CMT decrease was significant (p < 0.05). There were no significant differences in the mean changes of BCVA and CMT between both groups at 6 months.
  
  
  CONCLUSIONS
  The difference in the effectiveness of IVR between both groups was not significant. IVR can be a treatment option even for vitrectomized DME eyes.
authors.affiliation: Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Koyanagi
authors.forename: Shigeo
authors.initials: S
authors.lastname: Yoshida
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Yuki
authors.initials: Y
authors.lastname: Kubo
authors.forename: Muneo
authors.initials: M
authors.lastname: Yamaguchi
authors.forename: Takahito
authors.initials: T
authors.lastname: Nakama
authors.forename: Shintaro
authors.initials: S
authors.lastname: Nakao
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Ohshima
authors.forename: Tatsuro
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Koh-Hei
authors.initials: KH
authors.lastname: Sonoda
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003930:Diabetic Retinopathy / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069579:Ranibizumab / Q000008:administration & dosage*; D013997:Time Factors; D014792:Visual Acuity; D014821:Vitrectomy
chemical_list: D005938:Glucocorticoids; D000069579:Ranibizumab